Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Considering the likely abundance ratio of 244Pu to 238U in the early solar system (~0.008), this upper limit is still 18 times greater than the expected present 244Pu content in the bastnasite sample (1.2×10−21 g/g). Live interstellar plutonium-244 has been detected in meteorite dust in marine sediments, though the levels detected are much lower than would be expected from current modelling of the in-fall from the interstellar medium. Trace amounts of 244Pu were also found in rock from the Pacific ocean by a Japanese oil exploration company. It is important to recall, however, that in order to be a primordial nuclide – one whose origin lay in the amalgam orbiting the Sun that ultimately coalesced into the Earth – the plutonium-244 must have comprised some of the solar nebula, rather than having been replenished by extrasolar meteoritic dust.
Airstrikes on industrial and fuel hubs have released a chronic toxic cocktail of benzene, heavy metals, and persistent 'forever chemicals' (PFAS), triggering 'black rain' in major cities and causing long-term health degradation for civilians. The high oil prices driven by wars in the Middle East, including Iran, created a surge in profits of oil companies, pushing them to increase production as opposed to targets set by the Paris climate agreement. The planned expansion is projected to exceed the International Energy Agency's regular scenario – a 5.9% increase in oil and gas production in the 2020s, leading to a 2.9 °C (5.2 °F) global temperature increase.
(2026) study the visibility of fallow deer in broad-leaved woodland environment, and interpret purported hunting lesions on fossil bones of fallow deer as placed in areas that would be visible to Palaeolithic hunters in such environments. Evidence indicating that Aurignacian artifacts from cave sites in southwestern Germany were adorned with geometric sign sequences of comparable complexity to that of early proto-cuneiform is presented by Bentz & Dutkiewicz (2026). Conard, Janas & Zeidi (2026) report the discovery of two Aurignacian bird figurines made from mammoth ivory in the Hohle Fels cave (Germany). Isle de Beauchaine et al. (2026) study the morphology of teeth in the Aurignacian mandible Les Rois 2 from the Les Rois cave (Charente, France), interpreted as consistent with assignment of the specimen to an anatomically modern human. Röding et al. (2026) study the morphology of the Late Pleistocene frontal bone from Hahnöfersand (Germany) described by Bräuer (1980), interpret it as falling within the variability of Holocene Homo sapiens, and find no evidence of a morphology intermediate between those of Neanderthals and modern humans. Bossoms Mesa et al. (2026) report evidence of preservation of human DNA in pigment samples collected in and around Paleolithic rock art, including preservation of DNA resulting from deposition through direct human contact in the Escoural Cave (Portugal).
== Chemistry == Chemical constituents of the roots (Radix Astragali) include polysaccharides and triterpenoids (such as astragalosides), as well as isoflavones (including kumatakenin, calycosin, and formononetin) and their glycosides and malonates. It contains the saponin cycloastragenol.
Sources: en.wikipedia.org
Although spironolactone poses an important risk of hyperkalemia in the elderly, in those with kidney or cardiovascular disease, and/or in those taking medications or supplements, which increase circulating potassium levels, a large retrospective study found that the rate of hyperkalemia in young women without such characteristics who had been treated with high doses of spironolactone for dermatological conditions did not differ from those of controls. This was the conclusion of a 2017 hybrid systematic review of studies of spironolactone for acne in women, as well, which found that hyperkalemia was rare and was invariably mild and clinically insignificant. These findings suggest that hyperkalemia may not be a significant risk in such individuals, and that routine monitoring of circulating potassium levels may be unnecessary in this population. Other sources have claimed that hyperkalemia can nonetheless also occur in people with more normal renal function and presumably without such risk factors. Occasional testing on a case-by-case basis in those with known risk factors may be justified. Side effects of spironolactone that may be indicative of hyperkalemia and if persistent could justify serum potassium testing include nausea, fatigue, and particularly muscle weakness. Notably, reduced or no routine potassium monitoring with spironolactone in young women would reduce costs associated with its use. Among young, gender-diverse individuals taking spironolactone, hyperkalemia is rare and (if present) transient and asymptomatic.
=== 14 May === Russian missiles struck Ternopil Oblast, causing damage to civilian property. The Russian military claimed to have launched strikes on deployment points of Ukrainian forces and arms depots in the oblast as well as in Petropavlivka in Dnipropetrovsk Oblast. The Governor of Russia's Bryansk Oblast said a Ukrainian drone attack damaged a food processing facility in Starodub. The Russian Ministry of Defence confirmed the death of Colonels Vyacheslav Makarov and Yevgeny Brovko of the 4th Motorized Rifle Brigade during fighting in Bakhmut. The Russian military said it had repelled Ukrainian attacks in the north and south of Bakhmut while Yevgeny Prigozhin, head of the Wagner Group said his forces had advanced up to 130 metres (430 ft) over the past 24 hours. He also claimed control over 28 multi-story buildings in western districts of Bakhmut and estimated Ukrainian forces were still holding 20 buildings and a total area of 1.69 square km (0.65 square miles). Meanwhile, the Ukrainian Defence Ministry said its forces captured more than ten enemy positions in the north and south of Bakhmut and cleared a large area of forest near Ivanivske. The Washington Post, citing leaked documents from the Pentagon, reported that Prigozhin secretly contacted Ukrainian intelligence in January 2023 to reveal Russian military positions in exchange for a Ukrainian withdrawal from Bakhmut, which was refused, and advised them to advance towards Crimea while informing them of shortages in Russian ammunition.
Lundberg, M.D, recommended that third-party payers and the public should question paying for this procedure "until or unless additional honest experimentation demonstrates an actual effect." There is no good medical evidence for the effectiveness of therapeutic touch. A Cochrane systematic review, first published in 2004, found "[t]here is no robust evidence that TT promotes healing of acute wounds", but in 2016, the authors retracted it after the validity of the reviewed studies was questioned. The American Cancer Society notes, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases."
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.